NuPathe's iontophoretic patch issued notice of allowance by USPTO

NuPathe announced that the U.S. Patent and Trademark Office, or USPTO, has issued a notice of allowance for U.S. Patent application 13/407,434. This application relates to NuPathe's innovative iontophoretic patch that uses a two-stage delivery sequence to transdermally deliver sumatriptan. This, and other proprietary technology, is incorporated into NuPathe's lead product, ZECUITY (sumatriptan iontophoretic transdermal system), the first and only FDA approved patch for migraine.

View Comments (0)